uniQure N.V. Acquisitions, Net of Cash Acquired
uniQure N.V. (QURE) reported Acquisitions, Net of Cash Acquired of $1.90 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-02-27
- uniQure N.V. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00.
- uniQure N.V. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $1.08M.
- uniQure N.V. payments to acquire businesses, net of cash acquired for the quarter ending 2022-06-30 was $0.00.
- uniQure N.V. payments to acquire businesses, net of cash acquired for the quarter ending 2022-03-31 was $822.00K.
- uniQure N.V. payments to acquire businesses, net of cash acquired for fiscal 2022 was $1.90M, a 96.20% decline from fiscal 2021.
- uniQure N.V. payments to acquire businesses, net of cash acquired for fiscal 2021 was $49.95M.
- uniQure N.V. payments to acquire businesses, net of cash acquired for fiscal 2014 was $1.45M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.08M derived: sum of 2 quarters · filed 2025-02-27 | $1.08M derived: sum of 3 quarters · filed 2025-02-27 | $1.90M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.08M derived: sum of 2 quarters · filed 2023-11-07 | $1.90M 10-Q · filed 2023-11-07 | $1.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $822.00K 10-Q · filed 2023-08-01 | $822.00K derived: sum of 3 quarters · filed 2024-02-28 | |
| 2022-03-31 | $822.00K 10-Q · filed 2023-05-09 | $822.00K derived: sum of 2 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $49.95M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $49.95M 10-Q · filed 2022-11-02 | |||
| 2014-12-31 | $1.45M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |